XL-protein and Grifols Partner for Innovative Biopharmaceutical
XL-protein Partners with Grifols for Biopharmaceutical Development
Freising, Germany – XL-protein GmbH, recognized for its innovative approach in biopolymers aimed at pharmacokinetic optimization, has announced a partnership with Grifols, a leading global healthcare firm known for its plasma-derived treatments. This agreement establishes a worldwide License, Development, and Commercialization framework for creating a cutting-edge biopharmaceutical product.
Collaborative Advantage with PASylation Technology
The collaboration will allow XL-protein to utilize its advanced PASylation technology, which is currently at the clinical stage, to enhance the circulation of Grifols’ therapeutics. This partnership is expected to yield a more effective and prolonged treatment option for patients. Throughout this collaboration, XL-protein will provide significant preclinical support while Grifols retains the rights for further development, manufacturing, and marketing of the PASylated products.
Financial Implications of the Agreement
As part of the arrangement, XL-protein is set to receive an upfront payment alongside milestone payments corresponding to various stages like preclinical and clinical developments, regulatory approvals, and market success. Additionally, tiered royalties from sales of the resulting therapeutics under this partnership are also part of the agreement. Grifols will hold exclusive worldwide marketing rights to the products stemming from this collaboration.
Statements on Innovation and Collaboration
Dr. Jörg Schüttrumpf, Chief Scientific Innovation Officer at Grifols, expressed enthusiasm for the partnership, stating, "Grifols continues to innovate across its therapeutic portfolio to develop new treatments and enhancing existing ones for patients. We look forward to collaborating with XL-protein and combining our advanced scientific efforts in this leading initiative." This reflects a commitment to enhancing patient care through continuous innovation.
Incredible Potential of PASylation Technology
Dr. Michaela Gebauer, Managing Director of XL-protein, also conveyed excitement about the partnership, indicating that this collaboration not only enhances the pharmacological properties of existing therapeutics but also leverages XL-protein's PASylation technology alongside other new PASylated drugs that are under development. Uli Binder, another Managing Director at XL-protein, expressed that this union presents significant added value for Grifols.
About Grifols S.A.
Founded in Barcelona over a century ago, Grifols is dedicated to improving health and well-being globally. This global healthcare company is a leading name in essential plasma-derived medicines and transfusion medicine, crafting innovative healthcare solutions in over 110 countries. With its commitment to quality and innovation, Grifols maintains a vital role in the healthcare landscape.
About XL-protein GmbH
XL-protein GmbH is a privately held biotech company based near Munich, Germany. Specializing in the development of biologics that benefit from extended half-life and improved in vivo activity, XL-protein employs its proprietary PASylation technology, which can be applied to both established biopharmaceuticals and new therapeutic proteins, peptides, or small molecule drugs. This innovative approach allows for reduced dosing frequency while ensuring enhanced patient tolerability.
Contact Information
For more inquiries, reach out to XL-protein GmbH. Uli Binder, Managing Director, can be contacted via phone at +49-8161-53730-90 or by email at bd@xl-protein.com.
Frequently Asked Questions
What is the recent collaboration between XL-protein and Grifols about?
The collaboration aims to develop a novel biopharmaceutical product using XL-protein's PASylation technology to enhance Grifols' therapeutics.
What is PASylation technology?
PASylation is a clinical-stage technology utilized to extend the half-life and improve the performance of biologics, allowing for less frequent dosing.
How will this partnership benefit patients?
This collaboration is expected to develop more effective and long-lasting treatments, providing patients with better therapeutic options.
What financial terms are involved in the agreement?
XL-protein will receive upfront and milestone payments as well as royalties on sales from the therapies developed under the partnership.
Where is XL-protein GmbH located?
XL-protein GmbH is located near Munich, Germany, and focuses on innovative biopharmaceutical developments.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.